Southwest Securities·2026-02-06 06:37Group 1: JPM Conference Overview - The J.P. Morgan Healthcare Conference is one of the largest and most influential gatherings in the global healthcare sector, covering pharmaceuticals, biotechnology, medical devices, diagnostics, digital health, and healthcare services [3] - The conference serves as a platform for multinational corporations (MNCs), biotech firms, and investment institutions to connect, providing clear signals for industry development over the coming year [4] - The 2026 JPM Conference will be held from January 12 to 15 in San Francisco, California [5] Group 2: MNC Strategic Positioning and BD Strategies - In 2026, MNCs are focusing on four key areas: neuroscience, immunology, oncology, and cardiovascular diseases [6] - Business development (BD) transactions are becoming a core strategy for MNCs, with a shift towards precision and rationality in BD deals, emphasizing next-generation immunotherapies, cell therapies, and gene therapies [6] - AI is increasingly integrated into drug development, clinical design, and operational management across the industry [6][18] Group 3: Investment Opportunities in Innovative Drugs - The acceleration of BD transactions abroad is expected to inject new performance growth and market value elasticity, with a notable increase in projects and upfront payments in 2025 [8] - Policy support for innovative drugs is improving, with recent measures from health authorities aimed at fostering high-quality development in the sector [8] - Key clinical data releases and commercialization milestones for several innovative drugs are anticipated in 2025, which could significantly impact market valuations [8] Group 4: Key Domestic Companies and Their Focus - Companies like Hengrui Medicine and BeiGene are expected to achieve significant milestones in 2026, including multiple new drug applications and clinical data releases [24][25] - Hengrui Medicine aims to leverage a dual strategy of R&D and BD, with over 25 ongoing Phase III clinical trials and a target of more than 10 new drug approvals [24] - BeiGene is positioned to capitalize on its leading products in the chronic lymphocytic leukemia (CLL) space, with several key regulatory submissions and clinical trials planned for 2026 [29][35]